Proteomics and Biomarkers, Max Planck Institute of Psychiatry, Munich, Germany.
Int Rev Neurobiol. 2011;101:1-17. doi: 10.1016/B978-0-12-387718-5.00001-8.
Biomarkers are in demand for disease diagnosis, treatment response monitoring, and development of novel therapeutics. Biomarker discovery in neuroscience is challenging due to absence of robust molecular correlates and the interpatient heterogeneity that characterizes neuropsychiatric disorders. Because of the complexity of these disorders, a panel of biomarkers derived from different platforms will be required to precisely reflect disease-related alterations. Animal models of psychiatric phenotypes as well as -omics and imaging methodologies are important tools for biomarker discovery. However, the limitations of current research concerning sample handling and collection, candidate biomarker validation, and a lack of interdisciplinary approaches need to be addressed. Ultimately, the coordinated effort of relevant stakeholders including researchers, physicians, and funding organizations together with standardization initiatives will be vital to overcome the present challenges and to advance personalized health care using sensitive and specific biomarkers.
生物标志物在疾病诊断、治疗反应监测和新型治疗药物的开发方面有需求。由于缺乏稳健的分子相关性和神经精神疾病所具有的个体间异质性，神经科学中的生物标志物发现具有挑战性。由于这些疾病的复杂性，需要来自不同平台的一组生物标志物来精确反映与疾病相关的改变。精神表型的动物模型以及组学和成像方法是生物标志物发现的重要工具。然而，目前在样本处理和采集、候选生物标志物验证以及缺乏跨学科方法方面的研究存在局限性，需要加以解决。最终，包括研究人员、医生和资助组织在内的相关利益攸关方的协调努力，以及标准化举措，对于克服当前的挑战和利用敏感和特异性生物标志物推进个性化医疗至关重要。
